Compare State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF (SJNK) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF vs TransMedics Group Inc — how do they compare? State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF trades at $24.69, while TransMedics Group Inc trades at $85.89 (market cap $3.06B). The key difference: TransMedics Group Inc is trading nearer its 52-week high, State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF nearer its low. Which is the better fit depends on your goals.
| SJNK | TMDX | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $25.63 | $150.42 |
52-Week Low | $24.67 | $61.99 |
Market Cap | — | $3.06B |
Enterprise Value | — | $3.46B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SJNK, the SPDR Bloomberg Short Term High Yield Bond ETF, trades at $24.70 with minimal daily movement (-0.04%). Technical indicators show a bearish trend with moving averages signaling strong selling pressure, though oscillators are neutral. The ETF continues its regular dividend distributions, with recent payments of $0.14-0.15 per share. Institutional activity shows mixed sentiment with some firms reducing positions.
The outlook remains cautious given the bearish technical signals and institutional selling pressure. While the ETF provides consistent dividend income, high-yield bond markets face headwinds from potential yield increases and economic uncertainty. Investors should weigh the income generation against credit risk exposure in the current market environment.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF
SJNK invests in U.S. dollar-denominated high-yield corporate bonds with short-term maturities (under five years). It offers higher yields than investment-grade funds but with less interest rate sensitivity than longer-term junk bond ETFs.
Read more on SJNK →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
